StreetInsider.com News Articles

Vyome gets Chinese patent for besifloxacin acne gel

Wed, 01 Jul 2026 08:01:16 -0400

Vyome Holdings, Inc. (NASDAQ: HIND) announced that China's National Intellectual Property Administration has granted the company a patent covering formulation and therapeutic use claims for its besifloxacin topical gel program for inflammatory acne.

The patent, numbered ZL 2021 1 0758695.X, includes claims directed to the treatment of inflammatory acne, inflammation associated with acne, and acne involving antibiotic-resistant Propionibacterium acnes.

According to the company's press release, China's prescription acne market is estimated at approximately $600 million annually by 2035, based on third-party data.

Venkat Nelabhotla, Vyome's chief executive officer, said the patent "further enhances our strategic optionality in the immuno-inflammation space without changing our

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a patent (Chinese Patent No. ZL 2021 1 0758695.X) covering formulation

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Wed, 01 Jul 2026 08:00:00 -0400

Newly granted Chinese patent broadens Vyome's intellectual property estate with additional formulation and therapeutic use claims for besifloxacin gel in inflammatory acne, supporting future partnering, licensing and regional commercialization for this $600 million market
VT-1953 for malignant fungating wounds remains Vyome's flagship program and primary capital allocation priority

Form 8-K Vyome Holdings, Inc For: May 28

Fri, 29 May 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260529/26571167.html

Form 8-K Vyome Holdings, Inc For: May 28

Fri, 29 May 2026 08:43:00 -0400

si-local-file:///var/storage/secattach/20260529/26571167.html

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Thu, 28 May 2026 08:00:00 -0400

Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1
VT-1953 regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive FDA guidance on the next steps of development
Company ends Q1 2026 with approximately $8.8 million in cash and cash equivalents while maintaining a clean capital structure with no debt, no preferred stock, and no toxic financing instruments